Silexion Therapeutics LTD (SLXN)
1.07
-0.04 (-3.60%)
At close: Feb 28, 2025, 3:59 PM
1.09
1.40%
After-hours: Feb 28, 2025, 05:29 PM EST
No 1D chart data available
| Bid | 1.09 |
| Market Cap | 9.05M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -13.22 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | -3.17 |
| Analyst | Buy |
| Ask | 1.1 |
| Volume | 607,537 |
| Avg. Volume (20D) | 12,881,936 |
| Open | 1.05 |
| Previous Close | 1.11 |
| Day's Range | 1.03 - 1.14 |
| 52-Week Range | 0.21 - 13.56 |
| Beta | 0.02 |
About SLXN
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 16, 2024
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol SLXN
Website https://silexion.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SLXN stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 737.21% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
4 days ago
+64%
Silexion therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
1 month ago
+132.76%
Silexion Therapeutics shares are trading higher after the company reported new preclinical data for SIL-204 showing significant tumor reduction in pancreatic cancer models.
